Rohan Hoare has been named the new Chief Operating Officer (COO) of Houston-based Cyberonics, a medical technology company working in neuromodulation. Previously, Hoare served as Senior Vice President of Strategic Planning, an executive position he accepted back in September of 2013. Now, Hoare’s new promotion to COO is part of Cyberonics’ newfound effort to further invest in the epilepsy franchise of the company, focusing on development, manufacturing, quality, and commercial activities.
In addition, O’Neill F. D’Cruz will serve as the new Chief Medical Officer of Cyberonics. According to Cyberonics CEO Dan Moore, with these two changes, the executive team is now restructured to better focus their efforts on epilepsy market-development activities.
“Cyberonics’ market position in the treatment of refractory epilepsy has never been stronger; yet, refractory epilepsy is still underserved,” explained Rohan Hoare. “I am committed to increasing awareness of VNS Therapy® as a foundational therapeutic option and achieving maximum returns from our investments in sales, marketing and new technology in the form of revenue, profitability and increased market penetration.”
Before joining the company to head the business strategy development, Dr. Hoare served as President of St. Jude Medical’s Neuromodulation Division, and also worked for McKinsey & Co., a strategy consulting firm with expertise and clients specifically in high tech, med tech, and healthcare. Prior to his professional career, Hoare received his Master of Arts and a Ph.D. in Physics at Harvard University.
Dr. D’Cruz has a Master of Business Administration from the Kenan-Flagler Business School, UNC-Chapel Hill. He has served as Medical Director in Neurology at UCB, and has been teaching both Neurology and Pediatrics at University of North Carolina-Chapel Hill prior to his new position with the company. With more than two decades of experience in epilepsy, he is also known for his work in business development, clinical development, pharmacovigilance, public-private partnerships, and regulatory interactions.
In addition, Cyberonics has also begun to invest heavily in its operations.”We have made significant, multi-year investments in our sales force capabilities and our technology pipeline,” said Moore, adding that one of the company’s primary medical device focuses, “The AspireSRTM pulse generator, with seizure detection and response technology, recently received CE-mark approval in Europe, and the CentroTM and ProGuardianTM products are nearing regulatory submissions.”